CUSTOM DERMATOLOGY SEARCH:
Hormonal Agents Approved for Treatment of Acne
J.K.L. Tan, MD, FRCPC
What is Acne?
Acne is an occlusional and inflammatory disorder of pilosebaceous follicles (oil pores) resulting from the combined effects of:
Hormonal agents have long been recognized as being effective for treating acne in women. This paper focuses on agents officially indicated for treatment of acne in Canada:
These agents may be used in women with:
Spironolactone is a synthetic steroid antiandrogen that competitively binds androgen receptors, inhibits 5-alpha-reductase activity, and reduces androgen biosynthesis. It has been used for treatment of acne in doses ranging from 50- 200mg/day. Due to the limited number of trials and small sample sizes, the efficacy of spironolactone for treatment of acne has been deemed indeterminate by a recent Cochrane review.[Farquhar C, et al. The Cochrane Library (Oxford) 2; CD000194 (2003).]
While improvement in acne is generally noted by the second cycle with these agents, longer treatment durations of
6 cycles or more provide for greater effectiveness.
Summary of Evidence
Comparing Hormonal Treatments
While there are no controlled clinical trials on the relative efficacy of these 3 agents in treating acne, a survey of Canadian acne patients previously treated with these agents indicated that
[Tan J. Effectiveness of Hormonal Treatment in Acne – The Canadian Acne Epidemiological Survey. Presented at: Dermatology Update 2005, Montreal, Canada.]
The use of these agents may be associated with minor adverse events such as nausea, breast tenderness, headaches, mood changes, and weight gain. Serious potential complications include venous thromboembolism (VTE), myocardial infarction, and stroke. While the risk of low-dose combined hormonal treatments for venous thromboembolism (VTE) is increased 3-4 fold, the magnitude of this risk is of minimal clinical significance in women without additional risk factors [Contraception Guidelines Committee of SOGC. Canadian Clinical Practice Guidelines: Combined Hormonal Contraception. J Obstet Gynaecol Can 26(3):219-54 (2004).] A recent comprehensive epidemiological review did not demonstrate an increase in VTE risk for Diane®-35 [Spitzer WO. J Obstet Gynaecol Can 25:1011-8 (2003)]. Hypertension and smoking are independent risk factors for myocardial infarction and stroke in patients taking oral contraceptive pills. Accordingly, conditions contraindicating the use of hormonal treatments include VTE, cerebrovascular or coronary artery disease, headaches with focal neurologic symptoms, diabetes with complications, cigarette smoking >35 years, hypertension >160/100mmHg or with concomitant vascular disease, and conditions associated with prolonged immobilization.
Hormonal agents are important, effective therapeutic options for women across the spectrum of acne severity. The three preparations approved in Canada for this indication have safety profiles similar to conventional oral contraceptives.
All content ©2004-2014 SkinTherapyLetter® |
Last modified: Thursday, 19-Feb-2015 17:33:36 MST